Gene expression profiling of benign and malignant pheochromocytoma
- PMID: 17102123
- PMCID: PMC5560485
- DOI: 10.1196/annals.1353.058
Gene expression profiling of benign and malignant pheochromocytoma
Abstract
There are currently no reliable diagnostic and prognostic markers or effective treatments for malignant pheochromocytoma. This study used oligonucleotide microarrays to examine gene expression profiles in pheochromocytomas from 90 patients, including 20 with malignant tumors, the latter including metastases and primary tumors from which metastases developed. Other subgroups of tumors included those defined by tissue norepinephrine compared to epinephrine contents (i.e., noradrenergic versus adrenergic phenotypes), adrenal versus extra-adrenal locations, and presence of germline mutations of genes predisposing to the tumor. Correcting for the confounding influence of noradrenergic versus adrenergic catecholamine phenotype by the analysis of variance revealed a larger and more accurate number of genes that discriminated benign from malignant pheochromocytomas than when the confounding influence of catecholamine phenotype was not considered. Seventy percent of these genes were underexpressed in malignant compared to benign tumors. Similarly, 89% of genes were underexpressed in malignant primary tumors compared to benign tumors, suggesting that malignant potential is largely characterized by a less-differentiated pattern of gene expression. The present database of differentially expressed genes provides a unique resource for mapping the pathways leading to malignancy and for establishing new targets for treatment and diagnostic and prognostic markers of malignant disease. The database may also be useful for examining mechanisms of tumorigenesis and genotype-phenotype relationships. Further progress on the basis of this database can be made from follow-up confirmatory studies, application of bioinformatics approaches for data mining and pathway analyses, testing in pheochromocytoma cell culture and animal model systems, and retrospective and prospective studies of diagnostic markers.
Similar articles
-
Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy.J Clin Endocrinol Metab. 2007 Dec;92(12):4865-72. doi: 10.1210/jc.2007-1253. Epub 2007 Sep 18. J Clin Endocrinol Metab. 2007. PMID: 17878247
-
Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling.Ann Surg. 2009 Dec;250(6):983-90. doi: 10.1097/SLA.0b013e3181b248bb. Ann Surg. 2009. PMID: 19661783
-
Development of novel tools for the diagnosis and prognosis of pheochromocytoma using peptide marker immunoassay and gene expression profiling approaches.Ann N Y Acad Sci. 2006 Aug;1073:533-40. doi: 10.1196/annals.1353.057. Ann N Y Acad Sci. 2006. PMID: 17102122
-
Diagnostic management of benign and malignant pheochromocytoma.Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):155-9. doi: 10.1055/s-2007-970410. Exp Clin Endocrinol Diabetes. 2007. PMID: 17427102 Review.
-
Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.Adv Anat Pathol. 2015 Sep;22(5):283-93. doi: 10.1097/PAP.0000000000000086. Adv Anat Pathol. 2015. PMID: 26262510 Review.
Cited by
-
Advances in Nanotechnology for Cancer Immunoprevention and Immunotherapy: A Review.Vaccines (Basel). 2022 Oct 16;10(10):1727. doi: 10.3390/vaccines10101727. Vaccines (Basel). 2022. PMID: 36298592 Free PMC article. Review.
-
Investigating the role of somatic sequencing platforms for phaeochromocytoma and paraganglioma in a large UK cohort.Clin Endocrinol (Oxf). 2022 Oct;97(4):448-459. doi: 10.1111/cen.14639. Epub 2021 Dec 6. Clin Endocrinol (Oxf). 2022. PMID: 34870338 Free PMC article. Review.
-
Potential Biomarkers of Metastasizing Paragangliomas and Pheochromocytomas.Life (Basel). 2021 Nov 4;11(11):1179. doi: 10.3390/life11111179. Life (Basel). 2021. PMID: 34833055 Free PMC article. Review.
-
The Roles of PI3K/AKT/mTOR and MAPK/ERK Signaling Pathways in Human Pheochromocytomas.Int J Endocrinol. 2016;2016:5286972. doi: 10.1155/2016/5286972. Epub 2016 Nov 20. Int J Endocrinol. 2016. PMID: 27990160 Free PMC article.
-
Phenylethanolamine N-methyltransferase downregulation is associated with malignant pheochromocytoma/paraganglioma.Oncotarget. 2016 Apr 26;7(17):24141-53. doi: 10.18632/oncotarget.8234. Oncotarget. 2016. PMID: 27007161 Free PMC article.
References
-
- Eisenhofer G, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr. Relat. Cancer. 2004;11:423–436. - PubMed
-
- Rao F, Keiser HR, O'connor DT. Malignant pheochromocytoma: chromaffin granule transmitters and response to treatment. Hypertension. 2000;36:1045–1052. - PubMed
-
- O'riordain DS, et al. Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J. Surg. 1996;20:916–921. discussion 922. - PubMed
-
- Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J. Urol. 1992;147:1–10. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical